ACHILLION PHARMACEUTICALS, INC. Patent applications |
Patent application number | Title | Published |
20150239921 | Phosphonate Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R | 08-27-2015 |
20150239920 | Ether Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R | 08-27-2015 |
20150239919 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R | 08-27-2015 |
20150239895 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R | 08-27-2015 |
20150239894 | Amino Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R | 08-27-2015 |
20150239893 | Amide Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R | 08-27-2015 |
20150239868 | Alkyne Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R | 08-27-2015 |
20150239838 | Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer. | 08-27-2015 |
20150239837 | Factor D Inhibitors Useful for Treating Inflammatory Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer. | 08-27-2015 |
20140309189 | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV - A deuterated nucleoside analog of the formula | 10-16-2014 |
20140309164 | DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV - Deuterated nucleoside analogs of Formula (I) and the pharmaceutically acceptable salts thereof are provided by this disclosure | 10-16-2014 |
20140275520 | PROCESS FOR MAKING A 4-AMINO-4-OXOBUTANOYL PEPTIDE CYCLIC ANALOGUE, AN INHIBITOR OF VIRAL REPLICATION, AND INTERMEDIATES THEREOF - The invention provides a process of preparing 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Compound I | 09-18-2014 |
20140275480 | NOVEL PROCESSES FOR PRODUCING SOVAPREVIR - The disclosure includes novel processes for producing Sovaprevir comprising adding | 09-18-2014 |
20140275163 | SOVAPREVIR POLYMORPHS AND METHODS OF MANUFACTURE THEREOF - The disclosure provides crystalline Sovaprevir forms. The crystalline forms of Sovaprevir comprise a Form A polymorph, a Form B polymorph, a Form C polymorph, a Form D polymorph, and a Form E polymorph. The Form A, B, C, D, and E polymorphs exhibit X-ray powder diffraction patterns having peak locations in accordance with FIGS. | 09-18-2014 |
20140274914 | ACH-0142684 SODIUM SALT POLYMORPH, COMPOSITION INCLUDING THE SAME, AND METHOD OF MANUFACTURE THEREOF - The disclosure provides a crystalline sodium salt of ACH-0142684 comprising a Form A polymorph, a Form B polymorph, a Form C polymorph, a Form D polymorph, a Form E polymorph, a Form F polymorph, a Form G polymorph, a Form H polymorph, a Form I polymorph, or a combination thereof, wherein the Form A, B, C, D, E, F, G, H, and I polymorph exhibits an X-ray powder diffraction pattern having peak locations in accordance with FIGS. | 09-18-2014 |
20140271855 | SOVAPREVIR TABLETS - The disclosure includes tablet cores comprising Sovaprevir and a crystal growth inhibitor selected from hydroxypropyl methyl cellulose (HPMC), HPC (hydroxypropyl cellulose), hypromellose acetate succinate (HPMCAS), polyvinyl pyrrolidone (PVP), copovidone (PVP-VA), a copolymer of methacrylic acid and ethyl acrylate, or any combination of the foregoing, wherein ratio of Sovaprevir to crystal growth inhibitor is from about 40:60 (w/w) to about 60:40 (w/w). The disclosure further includes film coated tables. The disclosure also includes methods of treating HCV with the tablets described herein. | 09-18-2014 |
20140206604 | 4-AMINO-4-OXOBUTANOYL PEPTIDE CYCLIC ANALOGUES, INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Formula I | 07-24-2014 |
20140113890 | NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptides of Formula I | 04-24-2014 |
20130165471 | 2-SUBSTITUTED-THIENOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS - Disclosed herein are 2-substituted-thienoquinolones and related compounds and their pharmaceutically acceptable salts useful as antiviral agents and having the general formula | 06-27-2013 |
20120302538 | SUBSITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS - The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I | 11-29-2012 |
20120114601 | NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS - The invention provides certain compounds and salts of Formula I and Formula II: | 05-10-2012 |
20120108576 | THIAZOLE COMPOUNDS AND METHODS OF USE - The present invention provides compounds, salts and hydrates of Formula I, | 05-03-2012 |
20120040959 | 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS - The invention provides compound and salts of Formula I and II, disclosed herein, which includes compounds of Formula A and Formula B: | 02-16-2012 |
20110223132 | ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS - The invention provides compounds and salts of Formula I and Formula | 09-15-2011 |
20110213152 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES - The present invention provides process for synthesis of 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and 8A,9-dihydro-4aH-isothiazolo[5,4-b]quinoline-3,4-diones of the Formula A. | 09-01-2011 |
20110150997 | ELVUCITABINE PHARMACEUTICAL COMPOSITIONS - The invention provides novel pharmaceutical compositions of Elvucitabine. The invention also provides pharmaceutical compositions and oral dosage forms having unique physical-chemical properties. | 06-23-2011 |
20110070168 | MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I | 03-24-2011 |
20100292219 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION - The present invention provides tertiary amine substituted peptides of Formula (I) useful as inhibitors of HCV replication. The variables R and R | 11-18-2010 |
20100216725 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptides of Formula I | 08-26-2010 |
20100152103 | 4-AMINO-4-OXOBUTANOYL PEPTIDE CYCLIC ANALOGUES, INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Formula I | 06-17-2010 |
20100124545 | CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS - The invention provides cyclic carboxamide compounds and analogues thereof of Formula I | 05-20-2010 |
20100093018 | CELLS EXPRESSING CHIMERIC PROTEINS AND ASSAYS USING SUCH CELLS - Cells expressing chimeric hepatitis C virus NS4A protein are disclosed, as are vectors and methods for preparing such cells and methods of using the cells and the chimeric proteins therein in screening assays for detecting compounds that alter the associative characteristics of NS4A proteins. Disclosed screening assays are suitable for use in high throughput screening of compound libraries to identify compounds with a exhibiting specific anti-viral activity against hepatitis C virus. | 04-15-2010 |
20100029652 | Combination Therapy For Treating Hepatitis C Infections - The invention provides a method of treating hepatitis C, by providing compound of Formula I (shown below) in combination with a second active agent to a patient infected with the hepatitis C virus. Also provided herein are pharmaceutical combinations comprising a compound of Formula I and a second active agent. The pharmaceutical combination may be a unit dosage form or a packaged pharmaceutical composition. Packaged pharmaceutical combinations include a compound of Formula I and a second active agent in a package with instructions for using the formulation to treat a hepatitis C infection. | 02-04-2010 |
20090304605 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity - The invention provides amino-substituted aminothiazole compounds of Formula I and Formula II | 12-10-2009 |
20090082261 | UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides compounds urea-containing peptide compounds of Formula I | 03-26-2009 |
20090041720 | HETEROARYL SUBSTITUTED THIAZOLES - The invention provides heteroaryl substituted thiazolo compounds of Formula I and II | 02-12-2009 |
20090012071 | 4-SUBSTITUTED-1H-ISOTHIAZOLO[5,4-B][1,4]OXAZINO[2,3,4-IJ]QUINOLINE-7,8(2H,9H)-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS - The present invention provides compounds of the formula that possess antimicrobial activity. Certain compounds provided herein possess potent antibacterial, antiprotozoal, or antifungal activity. Particular compounds provided herein are also potent and/or selective inhibitors of microbial DNA synthesis and reproduction. The invention provides anti-microbial compositions, including pharmaceutical compositions, containing a compound of the invention and one or more or more carriers. The invention provides pharmaceutical compositions containing a 4-substituted- | 01-08-2009 |
20080207760 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv - The present invention relates generally to replicase complex defect inducers and pharmaceutical compositions containing such inducers. Methods of developing mutants that are resistant to replicase complex defect inducers are also provided. Further included are mutants that can be used in screening for replicase complex defect inducers. Methods of screening test compounds for the ability to induce the formation of replicase complex defects are also described. Also included are methods of inhibition of HCV replication by replicase complex defect inducers. | 08-28-2008 |